Efficacy of Buteyko Breathing in Seniors With Chronic Eustachian Tube Dysfunction

NCT ID: NCT07193485

Last Updated: 2025-09-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-05-12

Study Completion Date

2025-10-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Eustachian tube dysfunction is distressing probelm. drugs usually are not effective. compelemtary tehrapies like Buteyko breathing may be effective

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

forty seniors with Eustachian tube dysfunction (chronic obstructive form) will be ranomized to group I or group II. the group enroled 20 seniors. both groups wil take usual care (budesonide spray in nose in 64 microgram concentration one time per day plus the intake of a tablet two times daily containing containing 20-mg contration of pseudoephedrine hydrochloride and 5-mg concentration of loratadine) for 2 weeks. group I will aslo receive 30-min Buteyko breathing two times daily for 14 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Eustachian Tube Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

group number 1

twenty seniors with Eustachian tube dysfunction (chronic obstructive form) will bein group I and this group will take usual care (budesonide spray in nose in 64 microgram concentration one time per day plus the intake of a tablet two times daily containing containing 20-mg contration of pseudoephedrine hydrochloride and 5-mg concentration of loratadine) for 2 weeks. Also, group I will aslo receive 30-min Buteyko breathing two times daily for 14 weeks.

Group Type EXPERIMENTAL

Buteyko breathing

Intervention Type OTHER

twenty seniors with Eustachian tube dysfunction (chronic obstructive form) will be ranomized to group I and this group will take usual care (budesonide spray in nose in 64 microgram concentration one time per day plus the intake of a tablet two times daily containing containing 20-mg contration of pseudoephedrine hydrochloride and 5-mg concentration of loratadine) for 2 weeks. Also, group I will aslo receive 30-min Buteyko breathing two times daily for 14 weeks.

group number 2

Twenty seniors with Eustachian tube dysfunction (chronic obstructive form) will be ranomized to group II oand this group will take usual care (budesonide spray in nose in 64 microgram concentration one time per day plus the intake of a tablet two times daily containing containing 20-mg contration of pseudoephedrine hydrochloride and 5-mg concentration of loratadine) for 2 weeks.

Group Type ACTIVE_COMPARATOR

usual care

Intervention Type OTHER

twenty seniors with Eustachian tube dysfunction (chronic obstructive form) will be ranomized to group II and this group will take usual care (budesonide spray in nose in 64 microgram concentration one time per day plus the intake of a tablet two times daily containing containing 20-mg contration of pseudoephedrine hydrochloride and 5-mg concentration of loratadine) for 2 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Buteyko breathing

twenty seniors with Eustachian tube dysfunction (chronic obstructive form) will be ranomized to group I and this group will take usual care (budesonide spray in nose in 64 microgram concentration one time per day plus the intake of a tablet two times daily containing containing 20-mg contration of pseudoephedrine hydrochloride and 5-mg concentration of loratadine) for 2 weeks. Also, group I will aslo receive 30-min Buteyko breathing two times daily for 14 weeks.

Intervention Type OTHER

usual care

twenty seniors with Eustachian tube dysfunction (chronic obstructive form) will be ranomized to group II and this group will take usual care (budesonide spray in nose in 64 microgram concentration one time per day plus the intake of a tablet two times daily containing containing 20-mg contration of pseudoephedrine hydrochloride and 5-mg concentration of loratadine) for 2 weeks.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Eustachian Tube Dysfunction (chronic obstructive form)
* unilateral ear affetion
* senior patients
* chronci affection more than 3 months

Exclusion Criteria

* obesity
* cardiac probelms repsiratory problems
Minimum Eligible Age

65 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cairo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ali Mohamed Ali ismail

lecturer of physical therapy for Cardiovascular, Respiratory disorder and Geriatrics, Faculty of Physical Therapy, Cairo University

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ali MA Ismail, lecturer

Role: PRINCIPAL_INVESTIGATOR

Cairo University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cairo University

Dokki, Giza Governorate, Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ali MA Ismail, lecturer

Role: CONTACT

01005154209

Ali mohamed, lecturer

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

ali AM Ismail, lecturer

Role: primary

+201005154209

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB00014233-36

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.